

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/47	A1	(11) International Publication Number: WO 94/02144 (43) International Publication Date: 3 February 1994 (03.02.94)
(21) International Application Number: PCT/EP92/01640 (22) International Filing Date: 21 July 1992 (21.07.92) (71) Applicant (for all designated States except US): THE BOOTS COMPANY PLC [GB/GB]; 1 Thane Road West, Nottingham NG2 3AA (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : BUSSON, Mervyn [GB/GB]; REES, John, Andrew [GB/GB]; The Boots Company plc, 1 Thane Road West, Nottingham NG2 3AA (GB). (74) Agent: THACKER, Michael, Anthony; The Boots Company plc, Patents Department, R4 Pennyfoot Street, Nottingham NG2 3AA (GB).		(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: USE OF 7-FLUORO-1-METHYL-3-METHYLSULPHINYL-4-QUINOLONE IN THE TREATMENT OF ANGINA PECTORIS (57) Abstract A method and use are provided for the treatment of angina pectoris in humans, comprising the administration of an effective amount of 7-fluoro-1-methyl-3-methylsulphanyl-4-quinolone to a human in need of such treatment. Preferably the active compound is administered in an amount of at least 50 mg, once a day.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

USE OF 7-FLUORO-1-METHYL-3-METHYLSULPHINYL-4-QUINOLONE
IN THE TREATMENT OF ANGINA PECTORIS

The present invention relates to a method for the treatment of angina pectoris in humans.

Angina pectoris arises from an imbalance between myocardial oxygen supply and demand. Typically the condition results from narrowing of the coronary arteries through atherosclerosis. This reduces blood flow, and thus oxygen supply, to the heart muscles, resulting in a severe cardiac oxygen deficiency which can cause severe pain to the sufferer. The condition can, in extreme form, be life-threatening. Attacks of angina pectoris are commonly brought on by exercise or by stress which increase oxygen demand in the cardiac muscles to a point where it cannot be met by the reduced supply of blood thereto.


European Patent Publication No. 0149519A (The Boots Company PLC) discloses the use, in the treatment of heart failure, of quinolones of the following general formula (I):



wherein m is 0 or 1; n is 0, 1 or 2; and R is hydrogen, halo, methyl or trifluoromethyl.

Preferred compounds for such use are stated to be inter alia 7-fluoro-1-methyl-3-methylsulphanyl-4-quinolone and 1-methyl-3-methylsulphonyl-methyl-4-quinolone.

British Patent Application No. 8400905, one of two
priority documents submitted during prosecution of the
above European Patent Application, and thereby laid open
to public inspection, discloses quinolones of general
5 formula II



wherein n is 0, 1 or 2; R₁ is lower alkyl optionally
substituted by hydroxy, C₁₋₄ alkoxy carbonyl or C₁₋₄
alkoxy; allyl; propynyl or phenyl-lower alkyl in which
10 the phenyl ring is optionally substituted by 1 or 2 C₁₋₄
alkoxy groups or 1 or 2 C₁₋₄ alkyl groups; R₂ is C₁₋₄
alkyl, C₃₋₄ alkenyl or C₃₋₄ alkynyl with the proviso
that, when n is 0, R₂ is methyl; and R₃, R₄ and R₅,
which may be the same or different, are hydrogen, lower
15 alkyl, lower alkoxy, lower alkanoyl, halo,
trifluoromethyl or lower alkylthio.

It is stated in the specification that compounds of
formula II are "useful in the treatment of ischaemic
heart disease and/or heart failure". It is also stated,
20 later in the specification, that:
"It will be appreciated by those skilled in the art
that, in some cases, the patient may have ischaemic
heart disease or heart failure but that, in many cases,
the patient has both disorders. It will also be
25 appreciated that ischaemic heart disease includes angina
and myocardial infarction."

Members of the class of quinolones defined in
general formula II are thus disclosed to be of use in
the treatment of at least one disorder selected from

ischaemic heart disease and heart failure. The above-mentioned British Patent Application further states that:

5 "Some of the compounds, for example 7-fluoro-1-methyl-3-methylsulphiny-
1 methylsulphiny-4-quinolone, also have positive inotropic activity which is an advantage in the treatment of heart failure".

This is reflected in the later-filed European Application (EP-A-0149519) which states (page 7, line 26
10 to page 8, line 4) that:

" The inotropic activities of 7-fluoro-1-methyl-3-methylsulphiny-4-quinolone and 1-methyl-3-methylsulphonylmethyl-4-quinolone were determined by a method similar to that described by Marks, J.E. and Koch-Weser,
15 J. in Journal of Pharmacology and Experimental Therapeutics, 1971, Vol.78, No.1, pp 94-101. Intact left atria from guinea pigs were used in the determinations, and the animals were treated with reserpine, 5 mg/kg given intraperitoneally, 24 hours
20 before removal of the atria. It was found that both compounds have positive inotropic activity. "

This finding is confirmed inter alia by Falotico et al in J. Cardiovasc. Pharmacol. 14, 412-418, where it is reported (page 417) that:
25 "in electrically stimulated ferret papillary muscle, direct positive inotropic activity is observed with flosequinan and its sulfone derivative in concentrations ranging from 1 to 100µM. This complements hemodynamic studies in anaesthetised dogs ...". Similar results
30 are reported by Greenberg and Touhey in J. Cardiovasc. Pharmacol. 15, 900-1910.

Although thus clearly indicating use in the treatment of heart failure, British Patent Application No. 8400905 makes no specific reference to use of the

- 4 -

particular quinolone 7-fluoro-1-methyl-3-methylsulphinylmethyl-4-quinolone in treatment of ischaemic heart disease in any form, still less in the particular form known as angina pectoris.

5 To the contrary, in fact, the disclosure that this particular compound is a positive inotrope teaches the skilled worker away from use in treatment of angina pectoris.

By definition, positive inotropes cause the heart
10 to beat more vigorously, thus increasing oxygen demand from the heart muscles.

As noted above, angina pectoris results inter alia from cardiac oxygen deficiency caused by inadequate blood supply to the heart muscles. Accordingly, by
15 causing the heart to work harder, the administration of a positive inotrope to a patient suffering from angina pectoris would be expected to exacerbate the existing oxygen deficiency by increasing oxygen demand in the very muscles where oxygen supply is scarce, thus causing
20 a deterioration rather than an improvement, in the patient's condition.

7-Fluoro-1-methyl-3-methylsulphonyl-4-quinolone has also been found to have positive chronotropic activity in animals (see, for example, Yates et al, American
25 Heart Journal 1991, 121, pp. 974-983) which could also increase myocardial oxygen demand.

Furthermore, the known vasodilatory action of the present quinolone might cause preferential vasodilation of non-ischaemic coronary vessels, thus diverting blood
30 from diseased ischaemic coronary vessels and further reducing oxygen supply to the affected muscles of the

- 5 -

heart. This effect, known as "coronary steal" might cause further deterioration in the condition of angina.

Surprisingly, however, it has now been found that, despite the positive inotropy and chronotropy previously
5 shown by 7-fluoro-1-methyl-3-methylsulphonyl-4-quinolone in animals, this particular compound, when administered to humans suffering from angina, imparts a totally unexpected beneficial effect on the patient's condition.

According to the present invention, there is
10 provided a method for the treatment of angina pectoris in a human in need of such treatment, which comprises the administration to said human of a therapeutically effective amount of 7-fluoro-1-methyl-3-methylsulphonyl-4-quinolone.

15 The term "treatment" includes the therapeutic treatment of a human suffering from angina pectoris and the prophylactic treatment of a human at risk from angina pectoris. Therefore, the invention includes a method of preventing angina pectoris attack in a human
20 susceptible to such attack, by administering to said human an effective amount of 7-fluoro-1-methyl-3-methylsulphonyl-4-quinolone.

Preferably, the method of the invention is used in the long term prophylactic management of angina attacks.

25 The method of the invention may be used in humans who do or do not suffer from heart failure.

As used hereinafter, the term "the active compound" denotes 7-fluoro-1-methyl-3-methylsulphonyl-4-quinolone (also known as 'flosequinan'). In man, flosequinan is
30 naturally converted into the corresponding sulphone

- 6 -

compound 7-fluoro-1-methyl-3-methylsulphonyl-4-quinolone by metabolism following administration.

In the method of the present invention, the active compound may be administered enterally or parenterally.

5 Enteral administration may be oral or rectal. Parenteral administration may be intravenous, intramuscular, or topical. Oral administration is preferred for the treatment of chronic angina, but intravenous administration may be preferred in treating
10 the acute stage of the disease.

In the method of the present invention, the active compound is generally administered in the form of a pharmaceutical composition comprising the active compound together with a pharmaceutically acceptable
15 carrier. Such pharmaceutical compositions may take the form of any of the known pharmaceutical compositions for enteral or parenteral administration. Pharmaceutically acceptable carriers suitable for use in such compositions are well known in the art of pharmacy. The
20 compositions of the invention suitably contain 0.1-90% by weight of active compound. The compositions of the invention are often prepared in unit dosage form.

Suitably, the active compound is administered in a dose of at least about 50 mg per day since it has been
25 found that doses below about 50 mg do not always provide the benefit of the invention. Preferably the dose is at least about 75 mg per day, suitably between 75 mg and 150 mg per day, preferably between 75 mg and 125 mg per day, for example about 100 mg per day.

30 Suitably the active compound is administered as a single dose, once a day. This procedure has the advantage of being convenient to the patient and medical

personnel alike, and minimises the risk that the administration of medication will be overlooked. However, it will be understood that as an alternative, smaller doses could be provided several times a day to
5 provide a total dose of the size described.

Compositions for oral administration are the known pharmaceutical forms for such administration, for example tablets, capsules, syrups and aqueous or oily suspensions. The excipients used in the preparation of
10 these compounds are the excipients known in the pharmacist's art. Tablets may be prepared by mixing the active compound with an inert diluent such as calcium phosphate in the presence of disintegrating agents, for example maize starch, and lubricating agents, for
15 example magnesium stearate, and tableting the mixture by known methods. Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate. Similarly capsules, for example hard or soft gelatin
20 capsules, containing the active compound with or without added excipients, may be prepared by conventional means and, if desired, provided with enteric coatings in a known manner. Other compositions for oral administration include, for example, aqueous suspensions
25 containing the active compound in an aqueous medium in the presence of a non-toxic suspending agent such as sodium carboxymethylcellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example arachis oil.

30 Compositions for use in the invention suitable for rectal administration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa butter or polyethylene glycol bases.

- 8 -

Compositions for use in the invention suitable for parenteral administration are the known pharmaceutical forms for such administration, for example, sterile suspensions in aqueous and oily media or sterile solutions in a suitable solvent. Typically such forms might be solutions of glucose or sodium chloride.

Compositions for topical administration may comprise a matrix in which the active compound is dispersed so that the compound can be held in contact with the skin in order to administer the active compound transdermally. Alternatively, the active compound may be dispersed in a cream or ointment base.

In some formulations it may be beneficial to use the compounds of the present invention in the form of particles of very small size, for example, as obtained by fluid energy milling.

In the compositions of use in the present invention the active compound may, if desired, be associated with other compatible pharmacologically active ingredients, for example, nitrates (such as glyceryl trinitrate, pentaerythritol tetranitrate, isosorbide dinitrate and isosorbide mononitrate), β -blockers (such as acebutolol, atenolol, bisoprolol, metoprolol, carteolol, nadolol, oxprenolol, pinodol, propanolol, sotalol and timolol), calcium antagonists (such as verapamil, amlodipine, nicardipine, nifedipine and diltiazem) and Angiotensin Converting Enzyme (ACE) inhibitors (such as enalapril, lisinopril and captopril).

Thus, the invention provides a method as defined above, wherein the quinolone is administered simultaneously, sequentially or separately with a therapeutically effective amount of a calcium antagonist, a nitrate compound, or an ACE inhibitor.

There is also provided a product comprising 7-fluoro-1-methyl-3-methylsulphonyl-4-quinolone and a calcium antagonist or a nitrate compound, as a combined preparation for simultaneous, sequential or separate
5 administration in the treatment of angina pectoris in humans.

There is further provided a therapeutic composition for the treatment of angina pectoris which comprises a therapeutically effective amount of 7-fluoro-1-methyl-3-
10 methylsulphonyl-4-quinolone and a therapeutically effective amount of a calcium antagonist or a nitrate compound.

The present invention also provides the use of 7-fluoro-1-methyl-3-methylsulphonyl-4-quinolone in the
15 treatment of angina pectoris in humans.

The invention also provides the use of 7-fluoro-1-methyl-3-methylsulphonyl-4-quinolone in the manufacture of a medicament for the treatment of angina pectoris in humans.

20 Suitably in such uses, the dosage and manner of administration of the active compound are as described above.

It will be appreciated that, in some formulations, the active compound may be present in the form of a
25 therapeutically acceptable acid addition salt thereof.

The following are examples of compositions which may be used in accordance with the method of the present invention.

- 10 -

Composition 1

In the preparation of capsules, 100 parts by weight of 7-fluoro-1-methyl-3-methylsulphanyl-4-quinolone and 290 parts by weight of lactose are deaggregated and
5 blended. The mixture is filled into hard gelatin capsules, each capsule containing 100 mg of active compound.

Composition 2

In the preparation of capsules, 75 parts by weight
10 of 7-fluoro-1-methyl-3-methylsulphanyl-4-quinolone and 325 parts by weight of lactose are deaggregated and blended. The mixture is filled into hard gelatin capsules, each capsule containing 75 mg of active compound.

15 Composition 3

Tablets are prepared from the following ingredients:

		<u>Parts by weight</u>
20	7-fluoro-1-methyl-3-methyl-sulphanyl-4-quinolone	100
	Lactose (spray dried)	74
	Microcrystalline cellulose	74
	Maize starch	166
	Polyvinylpyrrolidone	13
25	Magnesium stearate	3.5
	Methylhydroxypropylcellulose	10
	Propylene glycol	1
	Titanium dioxide	3

The active compound, lactose, microcrystalline
30 cellulose and maize starch are deaggregated and blended.

- 11 -

The resulting mixture is granulated with a solution of the polyvinylpyrrolidone in denatured ethanol. The dry, sized granulate is blended with the magnesium stearate. The mixture is then compressed in a tabletting machine to give tablets containing 100 mg of flosequinan. The tablets are coated with a mixture of the methylhydroxypropyl cellulose, propylene glycol and titanium dioxide with water and denatured ethanol. All of the titanium dioxide and part of the methylhydroxy propyl cellulose are added as a suspension in denatured ethanol available under the trade name 'Opaspray White'.

Composition 4

Tablets are prepared from the following ingredients:

	<u>Parts by weight</u>
7-fluoro-1-methyl-3-methyl-sulphonyl-4-quinolone	100
Lactose (spray dried)	121
Microcrystalline cellulose	60
Croscarmellose sodium	33
Polyvinylpyrrolidone	13
Magnesium stearate	2.5
Methylhydroxypropyl cellulose	10
Propylene glycol	1
Titanium dioxide Ph Eur E171	3

The active compound, lactose, microcrystalline cellulose and croscarmellose sodium are deaggregated and blended. The resulting mixture is granulated with a solution of the polyvinylpyrrolidone in denatured ethanol. The dry, sized granulate is blended with the magnesium stearate. The mixture is then compressed in a tabletting machine to give tablets containing 100 mg of flosequinan. The tablets are coated with a mixture of the methylhydroxypropyl cellulose, propylene glycol and

- 12 -

titanium dioxide with water and denatured ethanol. All of the titanium dioxide and part of the methylhydroxy propyl cellulose are added as a suspension in denatured ethanol available under the trade name 'Opaspray White'.

5 Composition 5

Tablets are prepared from the following ingredients:

		<u>Parts by weight</u>
10	7-fluoro-1-methyl-3-methyl-sulphonyl-4-quinolone	100
	Lactose (spray dried)	120
	Microcrystalline cellulose	40
	Croscarmellose sodium	32
	Polyvinylpyrrolidone	13
15	Magnesium stearate	3
	Methylhydroxypropyl cellulose	10
	Propylene glycol	1
	Titanium dioxide	3

The active compound, lactose, microcrystalline
20 cellulose and croscarmellose sodium are deaggregated and blended. The resulting mixture is granulated with a solution of the polyvinylpyrrolidone in denatured ethanol. The dry, sized granulate is blended with the magnesium stearate. The mixture is then compressed in a
25 tabletting machine to give tablets containing 100 mg of flosequinan. The tablets are coated with a mixture of the methylhydroxypropyl cellulose, propylene glycol and titanium dioxide with water and denatured ethanol. All
30 of the titanium dioxide and part of the methylhydroxy propyl cellulose are added as a suspension in denatured ethanol available under the trade name 'Opaspray White'.

Composition 6

A formulation for intravenous injection is prepared to the following composition:

5	7 fluoro-1-methyl-3-methyl-sulphonyl-4-quinolone	100 mg
	Sodium chloride BP/USP for injections	900 mg
	Water for injections to	100 ml

10 The formulation is sterilised in the course of manufacture.

Composition 7

A formulation for intravenous injection is prepared to the following composition:

15	7-fluoro-1-methyl-3-methyl-sulphonyl-4-quinolone	100 mg
	Glucose BP/USP (pyrogen free)	5.5 g
	Water for injections to	100 ml

The formulation is sterilised in the course of manufacture.

20 The following non-limitative clinical example illustrates the invention.

Clinical Example

25 A clinical study was carried out in the form of a double-blind placebo controlled crossover trial conducted in two centres in the U.K. Patients fulfilling the entry criteria requiring a diagnosis of chronic, stable angina pectoris of at least three months

duration, without evidence of heart failure, myocardial infarction or stroke in the previous six months were eligible for the study. During a short run in period patients were weaned off any anti-anginal therapy, except emergency nitro-glycerine. They were then randomised to receive 100 mg of flosequinan daily, by oral administration, for seven days followed by a seven day wash out period and then seven days of placebo, or the treatments in the reverse order.

10 A Bruce Protocol Treadmill Test was used to elicit anginal symptoms and electrocardiographic changes and the times to these end points used as indicators of treatment efficacy. The exercise tests were performed immediately before and one hour after treatment with the trial medications on Day 1 and Day 14 (first day of each of the trial medications = acute response) and on Day 7 and Day 21 (last day of each of the trial medications = chronic response). Adverse events and nitro-glycerine consumption were recorded throughout the trial.

20 Thirty-seven patients entered and 23 completed the study. Exercise time significantly increased after the first and the seventh dose of flosequinan compared to placebo (38.8 and 48.6 seconds respectively). Flosequinan was also significantly superior to placebo in terms of time to achieve 1mm ST depression and the degree of ST depression after the first dose, the time to achieve maximum ST depression after the first and seventh dose. The remaining ECG parameters and consumption of nitro-glycerine tablets favoured flosequinan but did not achieve statistical significance.

The results from this study demonstrate that flosequinan has an unexpected beneficial effect in angina pectoris.

- 15 -

Claims

1. The use of 7-fluoro-1-methyl-3-methylsulphanyl-4-quinolone in the treatment of angina pectoris in humans.
2. The use of 7-fluoro-1-methyl-3-methylsulphanyl-4-quinolone in the manufacture of a medicament for the treatment of angina pectoris in humans.
3. A product comprising 7-fluoro-1-methyl-3-methylsulphanyl-4-quinolone and a calcium antagonist or a nitrate compound, as a combined preparation for simultaneous sequential or separate administration in the treatment of angina pectoris in humans.
4. A therapeutic composition for the treatment of angina pectoris which comprises a therapeutically effective amount of 7-fluoro-1-methyl-3-methylsulphanyl-4-quinolone together with a therapeutically effective amount of a calcium antagonist or a nitrate compound.
5. A method for the treatment of angina pectoris in a human in need of such treatment, which comprises the administration of a therapeutically effective amount of 7-fluoro-1-methyl-3-methylsulphanyl-4-quinolone to said human.
6. A method as claimed in claim 5 wherein the treatment comprises preventing angina attack in a human susceptible to such attack.
7. A method as claimed in claim 6 wherein the treatment comprises the long term prophylactic management of angina attacks.

- 16 -

8. A method as claimed in any one of the preceding claims wherein the quinolone is administered enterally.
9. A method as claimed in claim 8 wherein the quinolone is administered orally.
- 5 10. A method as claimed in any one of claims 5 to 7 wherein the quinolone is administered parenterally.
11. A method as claimed in claim 10 wherein the quinolone is administered by intravenous injection.
- 10 12. A method as claimed in any one of the preceding claims wherein the quinolone is administered at a dose of at least about 50 mg/day.
13. A method as claimed in claim 12 wherein the quinolone is administered at a dose of between 75 mg/day and 150 mg/day.
- 15 14. A method as claimed in claim 13 wherein the quinolone is administered at a dose of about 100 mg/day.
15. A method as claimed in any one of the preceding claims wherein the quinolone is administered in a single dose, once a day.
- 20 16. A method as claimed in any one of the preceding claims wherein the quinolone is administered simultaneously, sequentially or separately with a therapeutically effective amount of a calcium antagonist, a nitrate compound or an Angiotensin
- 25 Converting Enzyme (ACE) inhibitor.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 92/01640

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 A61K31/47

II. FIELDS SEARCHEDMinimum Documentation Searched⁷

Classification System

Classification Symbols

Int.Cl. 5

A61K

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸**III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹**

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	WO,A,9 010 445 (THE BOOTS COMPANY) 20 September 1990 see abstract see page 6, line 32 - page 7, line 4 see page 16, line 1 - line 9 ---	1-16
A	AMERICAN HEART JOURNAL vol. 121, no. 3, 1991, pages 974 - 983 D.B. YATES ET AL. 'PHARMACOLOGY OF FLOSEQUINAN' see the whole document, in particular page 976 --- -/--	1-2,5-16

¹⁰ Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

05 MARCH 1993

Date of Mailing of this International Search Report

23. 03. 93

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

HOFF P.J.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	JOURNAL OF CARDIOVASCULAR PHARMACOLOGY vol. 15, no. 6, 1990, pages 900 - 910 S. GREENBERG ET AL. 'POSITIVE INOTROPY CONTRIBUTES TO THE HEMODYNAMIC MECHANISM OF ACTION OF FLOSEQUINAN IN THE INTACT DOG' see the whole document ---	1-2,5-16
A	CHEMICAL ABSTRACTS, vol. 103, no. 22, 1985, Columbus, Ohio, US; abstract no. 183569e, 'USE OF QUINOLONES FOR TREATING CORONARY INSUFFICIENCY' & DE,A,3 500 756 (BOOTS CO.) 25 July 1985 see abstract ---	1-2,5-16
A	EP,A,0 149 519 (THE BOOTS COMPANY PLC) 24 July 1985 cited in the application see the whole document ---	1-2,5-16
A	DRUGS OF THE FUTURE vol. 11, no. 3, 1986, pages 177 - 178 R. MANNHOLD 'BTS-49465' see the whole document ---	1-2,5-16
X	INTERNATIONAL JOURNAL OF CARDIOLOGY vol. 24, 1989, pages 73 - 76 A. SCHNEEWEISS ET AL. 'THE EFFECT OF FLOSEQUINAN IN PATIENTS WITH HEART FAILURE OF ACUTE ONSET COMPLICATING ACUTE MYOCARDIAL INFARCTION' see the whole document -----	3-4

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 92/ 01640

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
ALTHOUGH CLAIMS 1,5-16 ARE DIRECTED TO A METHOD OF TREATMENT OF THE HUMAN/
ANIMAL BODY THE SEARCH HAS BEEN CARRIED OUT AND BASED ON THE ALLEGED EFFECT
S OF THE COMPOUND/COMPOSITION.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9201640
SA 62305

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 05/03/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9010445	20-09-90	AU-A- 5261690	09-10-90
		EP-A- 0527720	24-02-93
		JP-T- 4503806	09-07-92

EP-A-0149519	24-07-85	BE-A- 901489	15-07-85
		DE-A- 3500756	25-07-85
		US-A- 4552884	12-11-85
